Ventyx Ends Development of TYK2 Inhibitor After Phase II Flop in Crohn’s Disease

Back-to-back failures in psoriasis and Crohn’s disease have forced Ventyx Biosciences to abandon the development of its investigational oral TYK2 inhibitor VTX958.